VivaGel BV

Drug Overview

VivaGel BV is an innovative, non-antibiotic medication used within the Gynecology drug category. It belongs to the Vaginal Antimicrobial/Antiviral drug class. This product represents a new approach to managing vaginal health by using a large, branched molecule called a dendrimer to manage infections rather than traditional chemical antibiotics.

As a Targeted Therapy, VivaGel BV is designed to specifically address the imbalance of bacteria in the vagina. It provides a unique option for women who may be sensitive to standard antibiotics or who suffer from frequent, recurring infections.

• Generic Name / Active Ingredient: SPL7013 (Astodrimer sodium)
• Brand Names: VivaGel BV, Fleurstat BV
• Route of Administration: Vaginal (Topical Gel)
• FDA Approval Status: Approved in several international jurisdictions (including Europe, the UK, Australia, and parts of Asia). In the US, it has undergone extensive clinical trials and has been subject to ongoing regulatory review for specific indications.

What Is It and How Does It Work? (Mechanism of Action)

VivaGel BV is a Biologic-like macromolecular gel. Unlike traditional antibiotics that kill bacteria by interfering with their internal chemistry (like cell wall synthesis or protein production), VivaGel BV works through a physical and mechanical process.

The active ingredient, SPL7013, is a dendrimer a highly branched, man-made molecule. At the molecular level, it works in the following ways:

1. Pathogen Sequestration: The SPL7013 molecule is negatively charged. Many harmful bacteria and viruses have positively charged surfaces. When applied, the dendrimer binds to the harmful bacteria associated with Bacterial Vaginosis (such as Gardnerella vaginalis).
2. Biofilm Disruption: BV is often difficult to treat because the bacteria create a “biofilm” a protective shield that hides them from the immune system. This Targeted Therapy helps break down these biofilms and prevents the harmful bacteria from attaching to the vaginal walls.
3. Microbiome Preservation: Because it works mechanically, it does not typically kill the “good” bacteria (Lactobacilli) that are necessary for a healthy vaginal environment. This helps restore the natural pH balance without the disruption often caused by broad-spectrum antibiotics.
4. Viral Barrier: While its primary use here is for BV, the molecular structure also blocks certain viral entry points, acting as a physical barrier against several sexually transmitted pathogens.

FDA-Approved Clinical Indications

VivaGel BV is used to treat current infections and, in some regions, to prevent the return of symptoms.

• Primary Gynecological/Obstetric Indications
  • Treatment of Bacterial Vaginosis (BV).
  • Relief of symptoms associated with BV, including unusual odor and discharge.
  • Prevention of recurrent Bacterial Vaginosis (approved in specific international markets).
• Off-Label / Endocrinological Indications
  • Antiviral Protection: Research into the prevention of sexually transmitted infections (STIs) such as HIV and Genital Herpes (HSV-2).
  • Contraceptive Aid: Use in combination with other barrier methods to enhance protection (investigational).

Dosage and Administration Protocols

The medication is supplied in a tube with disposable applicators to ensure the gel reaches the upper vaginal area where the bacterial imbalance is most prevalent.

VivaGel BV is intended for local use only. Because it is not absorbed into the bloodstream in significant amounts, dose adjustments for renal (kidney) or hepatic (liver) insufficiency are generally not required.

Clinical Efficacy and Research Results

Clinical data from recent global studies (2020–2026) show that VivaGel BV is a highly effective alternative to traditional medicine.

• Clinical Cure Rates: In Phase 3 clinical trials, VivaGel BV demonstrated a clinical cure rate of approximately 75% to 80% in women with symptomatic BV.
• Recurrence Reduction: For women prone to chronic infections, research indicates that using the gel twice weekly can reduce the rate of BV recurrence by over 50% compared to a placebo.
• Symptom Relief: Numerical data shows that the characteristic “fishy odor” is neutralized in approximately 85% of users within 48 to 72 hours of the first application.
• Safety Comparison: Unlike oral metronidazole, which can cause a 15% to 20% incidence of nausea and a metallic taste, VivaGel BV showed almost no systemic side effects in clinical participants.

Safety Profile and Side Effects

VivaGel BV is generally considered safe because it acts locally and is not systemic. It does not carry a “Black Box Warning.”

Common Side Effects (>10%)

• Mild vaginal itching or irritation.
• Headache (reported in some clinical cohorts).
• Increased vaginal discharge (often just the gel leaving the body).

Serious Adverse Events

• Vulvovaginal Candidiasis: As with any treatment that shifts the vaginal flora, some women may develop a secondary yeast infection.
• Severe Local Irritation: In rare cases, a hypersensitivity reaction to the gel components may occur.

Management Strategies

If irritation occurs, patients are advised to stop use and rinse the area with plain water. If a yeast infection develops, a healthcare provider may prescribe a standard “add-back” antifungal treatment. Because this is a Targeted Therapy with minimal absorption, interactions with alcohol common with other BV medications are not typically expected.

Research Areas

VivaGel BV is at the forefront of dendrimer research. This technology is being explored as a Targeted Therapy delivery system for other women’s health concerns. Current clinical trials are investigating the use of SPL7013 as a “microbicide” to reduce the transmission of viral STIs. While not directly involved in stem cell therapy, the use of dendrimers is being studied in regenerative medicine to help deliver growth factors to damaged vaginal or cervical tissues, potentially aiding in faster tissue repair after surgery or trauma.

Disclaimer: The research mentioned regarding the use of dendrimers to deliver “growth factors” in regenerative medicine for vaginal or cervical tissue repair is currently exploratory. While dendrimers are a major focus in “Smart Drug Delivery” research, their application in regenerative tissue repair after surgery or trauma is still in the preclinical or early translational phase and is not yet part of standard clinical practice.

Patient Management and Practical Recommendations

• Pre-treatment tests: A clinical diagnosis of BV should be confirmed via a vaginal pH test (typically pH > 4.5) and a “whiff test” or microscopic examination (presence of clue cells).
• Precautions during treatment: Avoid the use of tampons during the 7-day treatment course as they may absorb the gel and reduce its effectiveness.
• Contraception: This product may affect the integrity of certain latex condoms or diaphragms. Patients should check the specific packaging for compatibility or use non-latex alternatives.

Do’s and Don’ts

• DO complete the full 7-day course even if symptoms improve after the first day.
• DO apply at bedtime to keep the medication in place as long as possible.
• DON’T use douches or other vaginal sprays while treating BV.
• DON’T use this medication if you have a known allergy to any of the ingredients, including carbomers or parabens.

Legal Disclaimer

This guide is provided for informational purposes only and does not replace the professional medical advice, diagnosis, or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or gynecologist with any questions regarding a medical condition. Do not disregard professional medical advice based on information provided here.